DIASORIN OBTAINS THE APPROVAL OF HEPATITIS, RETROVIRUS AND SYPHILIS TESTS ON ITS LIAISON XL PLATFORM IN CHINA

January 24, 2014 - Saluggia (VC) - DiaSorin (FTSE Mid Cap:DIA) is pleased to announce the obtainment of all the marketing approvals for Hepatitis, Retroviral and Syphilis assays on its LIAISON XL platform for the Chinese market.

With its complete panel for the pre-surgical screening testing, DiaSorin enters the hepatitis B, hepatitis C and Retrovirus’ segments in China, becoming the Company with the most complete offering for infectious diseases on a single platform in this market.

Concerning the market in China, estimates show a value of around $ 160 million, with a growth of approximately 20% per year in CLIA technology.

In this frame, DiaSorin strives to expand its footprint targeting the diagnostic lab activity of Hepatitis and Retroviruses testing and aims to become a player in this important segment, further enhancing and consolidating its positioning in the Chinese market.

Chen Even, Senior Corporate VP Commercial Operations, commented: “The Chinese market is growing rapidly and the demand for testing of infectious diseases is particularly strong. With the approval of these new tests we reach an important milestone and strengthen our presence in a market that will increasingly contribute more to the growth of Group in the near future”.

The new tests include the complete panel of hepatitis B, hepatitis C, HIV and Treponema Assays.

- **HBsAg Quant** for hepatitis B screening, diagnosis and monitoring - quantitative determination of hepatitis B surface antigen (HBsAg);
- **Anti-HBs II**, is a test for the quantitative determination of antibody to hepatitis B surface antigen (anti-HBs);
- **Anti-HBc**, is a test for the qualitative determination of total antibodies to hepatitis B core antigen (anti-HBc);
- **Anti-HBe**, is a test for the qualitative determination of total antibodies to hepatitis B “e” antigen (anti-HBe);
- **HBeAg**, is a test for the quantitative determination of “e” antigen of hepatitis B virus (HBeAg);
- **HCV Ab** for hepatitis C screening and diagnosis - qualitative determination of specific antibodies to hepatitis C virus (anti-HCV);
- **HIV Ab/Ag** for HIV screening and diagnosis - combined qualitative determination of p24 antigen and specific antibodies to human immunodeficiency viruses;
- **Treponema** for diagnosis of syphilis infection - qualitative determination of specific total antibodies to Treponema pallidum.
Mr. Carlo Rosa, CEO of DiaSorin Group, commented: “The approval of these tests shows the importance of CLIA technology even in booming markets, and confirms the validity of the Group’s strategy to converge its efforts in research and development of test tools and technology”.

About DiaSorin
Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD “diagnostics specialist”.

For additional information, please contact:

Riccardo Fava
External Relations Director - Head of IR and Media
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Margherita Sacerdoti
Investor Relations Specialist
Tel: +39.0161.487456
margherita.sacerdoti@diasorin.it